Unicycive Therapeutics, Inc.
Our development programs are focused on two kidney diseases with large unmet medical needs. We are developing Renazorb as a potent and selective second-generation phosphate binding agent using proprietary nanoparticle technology for the treatment of patients with hyperphosphatemia. We are also developing UNI-494, a patented pro-drug of a repurposed marketed agent with a target of improved safety and pharmacokinetics, for the treatment of patients with acute kidney injury.
Nasdaq: UNCY
IR Website: https://ir.unicycive.com/
Headquarters: Los Altos, CA
Content provided by Unicycive on 2-25-22.
TALK TO MANAGEMENT
The Unicycive Therapeutics management team is always available to talk to current and potential investors. They're happy to answer any questions you may have and tell you what makes their story unique. Please fill out this form, and we will connect you shortly.
Summary
Our development programs are focused on two kidney diseases with large unmet medical needs. We are developing Renazorb as a potent and selective second-generation phosphate binding agent using proprietary nanoparticle technology for the treatment of patients with hyperphosphatemia. We are also developing UNI-494, a patented pro-drug of a repurposed marketed agent with a target of improved safety and pharmacokinetics, for the treatment of patients with acute kidney injury.
Investor Presentation
Recent News
Unicycive Announces Renazorb Pre-clinical and Clinical Data Selected for Presentation at National Kidney Foundation Spring Clinical Meeting
Feb 2, 2022
Unicycive Therapeutics to Present at the H.C. Wainwright BIOCONNECT Virtual Conference
Jan 10, 2022
Unicycive Therapeutics Receives Confirmatory Guidance on Renazorb Regulatory Pathway
Nov 29, 2021
Unicycive Therapeutics Announces Third Quarter 2021 Financial Results
Nov 11, 2021
Unicycive Therapeutics Appoints Douglas Jermasek As Executive Vice President, Corporate Strategy
Oct 26, 2021
Management Overview
Shalabh Gupta (MD, CEO)
Chief Executive Officer, President and Director
Shalabh Gupta, our founder, has served as our Chief Executive Officer, President and director since August 2016. Since June 2013, Dr. Gupta has also served as the founder and Chief Executive Officer of Globavir Biosciences, Inc., a company focused on commercializing novel therapeutics and powerful diagnostics for treating global infectious disease. Dr. Gupta has also served in various other capacities including founder and Chief Executive Officer of Biocycive Inc.; Strategy, Genentech Commercial at Genentech, Inc.; Equity Research, Pharmaceuticals at UBS Investment Bank; Attending Physician at NYU Medical Center; clinical faculty member at NYU School of Medicine; and Equity Research, Biotechnology at Rodman & Renshaw, LLC. In addition, he has served on the board of directors of Beall Center for Innovation and Entrepreneurship since 2018. Dr. Gupta has also served as an advisor to SPARK, Stanford University School of Medicine since 2012, a charter member of TiE, a not-for-profit network of entrepreneurs fostering entrepreneurship, mentoring and education, since 2013.
Dr. Gupta previously served on the board of directors of Phenomenome Discoveries Inc. and was a Fellow at the Startup Leadership Program, a medical advisor Synageva BioPharma Corporation (formerly known as AviGenics) and an advisor to NYU Langone Medical Center (Office of Technology Transfer). Dr. Gupta received his MPA in health care finance and management from NYU Robert F. Wagner Graduate School of Public Service, and his medical degree from Jawaharlal Institute of Postgraduate Medical Education & Research, India. Furthermore, Dr. Gupta completed his internship in Internal Medicine, and medical residency in physical medicine and rehabilitation and a research fellowship in cardiopulmonary rehabilitation from New York University (“NYU”) School of Medicine and New York University. He practiced medicine from 2000 to 2008 at NYU’s various hospitals first during his medical training (2000-2004) and then as an attending physician (2004-2008).
Dr. Gupta also served as a faculty member at NYU School of Medicine. In the past, Dr. Gupta was a board-certified physician, and he currently holds a license from the California State Medical Board. While working as a stock analyst on Wall Street, Dr. Gupta held Series 7, 63, 86 and 87 licenses. We believe Dr. Gupta is qualified to serve as a member of our board of directors because of his background as a physician and as a biotechnology executive and his extensive experience in both in-licensing technologies from academic institutions and biotechnology companies as well as out-licensing technologies to larger organizations in addition to his former experience on Wall Street.
Pramod Gupta (PhD)
Executive Vice President, Pharmaceutical & Business Operations
Pramod Gupta, PhD, serves as the Executive Vice President of Pharmaceutical & Business Operations at Unicycive Therapeutics Inc. Previously, he worked as SVP of Pharmaceutical Operations at Spectrum Pharmaceuticals, Global VP at Bausch & Lomb, Senior Director of R&D at Baxter Healthcare, Director of R&D at TAP Pharmaceuticals (joint venture of Abbott & Takeda) and R&D Project Leader at Abbott Pharmaceuticals. During this time, Dr. Gupta developed, received regulatory approvals from US FDA and other international agencies, and commercialized over 40 pharmaceutical products. He received his PhD in Pharmaceutical Sciences from the University of Otago in New Zealand. He is holder of 12 granted patents, and he has published over 50 scientific papers.
Doug Jermasek (MBA)
Executive Vice President, Corporate Strategy
Douglas Jermasek joined Unicycive in 2021 as Executive Vice President, Corporate Strategy. Mr. Jermasek is a seasoned biopharmaceutical executive with over 25 years of commercial leadership experience in both U.S. and international markets. Most recently, he served as Senior Vice President, Marketing and Strategy at Akebia Therapeutics, a role he assumed after the merger with Keryx Biopharmaceuticals. Previously he spent over a decade at Genzyme (a Sanofi Company) culminating as Senior Vice President and General Manager, Head of Renal Global Business Unit. In that role, he drove sales of over $1 billion, establishing Renvela® as the standard of care for the treatment of hyperphosphatemia for patients with chronic kidney disease (CKD) and achieving “blockbuster” status globally. Earlier, he held management positions of progressive responsibility at Intercept Pharmaceuticals, Prometheus Laboratories, Agouron Pharmaceuticals, and Abbott Laboratories. Mr. Jermasek holds a Master’s degree in Business Administration from the Marriott School of Management at Brigham Young University and a Bachelor’s degree in Biological Science also from BYU.
Risks & Disclosures
This communication is neither an offer to sell nor a solicitation of an offer to buy, nor a recommendation of any securities of the company mentioned herein.
Unicycive Therapeutics Inc. (the “Company”) and its counsel have reviewed the content of this page as well as the accompanying presentation (“Company Presentation”) displayed on this page. To the best of its knowledge, the Company does not believe this content to be misleading or inaccurate in any material respect, nor does it believe there are any material omissions with respect to such content. The Company does not believe the contents of the page or the Company Presentation to contain any non-public material information.
Information and opinions presented in the Company Presentation are provided by the Company, and b2i digital makes no representation as to their accuracy or completeness. The information contained on this page is not intended to constitute any form of advice, and the information provided is not intended to provide a sufficient basis on which to make an investment decision. It is not investment research, nor does it constitute a research recommendation, as it does not constitute substantive research or analysis. This information is not to be relied upon in substitution for the exercise of independent judgment.
Information, opinions and estimates contained on this page or in the Company Presentation reflect judgments by the Company as of the original date of publication by the Company and are subject to change without notice. Past performance should not be taken as an indication or guarantee of future performance, and no representation or warranty, express or implied is made regarding future performance.
A complete description of the risks and uncertainties relating to the Company and its securities can be found in the company's filings with the U.S. Securities and Exchange Commission available for free at www.sec.gov.
Information on this page may relate to penny stocks, which may also be referred to as low-priced stocks. Penny stocks are low-priced shares typically issued by small companies. Penny stocks involve greater than normal risk, they may be less liquid than other stocks (i.e., more difficult to sell), and there may be less reliable information available regarding such stocks. Investors in penny stocks should be prepared for the possibility that they may lose their entire investment.
B2I DIGITAL, Inc. is a marketing sponsor of the Roth 34th Annual Roth Conference. B2I DIGITAL, Inc. is not an affiliate of Roth Capital Partners, LLC (“Roth”) and is not authorized to represent or act on behalf of Roth ,in any capacity. Roth has not reviewed and approved the content contained on the b2idigital.com website.
